To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults

NCT06931327 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-06-12

No results posted yet for this study

Summary

To evaluate the safety and pharmacokinetic characteristics of AJU-C711 in healthy adults

Conditions

Interventions

DRUG

Test Drug

AJU-C711

DRUG

Reference Drug

C711R

Sponsors & Collaborators

  • AJU Pharm Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-29
Primary Completion
2025-04-16
Completion
2025-04-18

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06931327 on ClinicalTrials.gov